Experts Question Strength of Data in Actos® Alzheimer’s Study
Experts are questioning the strength of data in a new study demonstrating that a diabetes medication created a slight decrease in the risk of a person developing Alzheimer’s.
As part of the recent study, researchers followed 145,717 people ages 60 or older who were taking the diabetes medicine Actos® (pioglitazone) and who were also part of Germany’s public insurer plan from 2004 to 2010. The findings, presented during the Alzheimer’s Association International Convention in Copenhagen, demonstrated that people taking Actos® were 6% less likely to develop dementia.
However, some experts are questioning the real-world significance of this study. Ben Wolozin, Professor at the Boston University Alzheimer’s Disease Center, says that the data may not provide much encouragement. While he believes the study is very important, he states, “it’s actually almost surprising to me that the lowering of relative risk was so weak.” Wolozin indicates that the study showing such a small effect is unlikely to translate into an observable difference in the real-world. Takeda, the manufacturer of Actos®, is trying again in a 5-year trial after it recruits 5,800 subjects for its study.
The choice of a lawyer is an important decision and should not be based solely on advertisements.